Evogene Ltd. (NASDAQ:EVGN – Get Free Report)’s share price crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $1.03 and traded as low as $0.8079. Evogene shares last traded at $0.8114, with a volume of 70,966 shares.
Evogene Stock Down 1.1%
The stock has a fifty day moving average price of $1.03 and a two-hundred day moving average price of $1.15. The company has a market capitalization of $4.36 million, a price-to-earnings ratio of -1.62 and a beta of 1.35.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its stake in shares of Evogene by 58.0% during the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 12,387 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Evogene during the fourth quarter valued at approximately $25,000. Finally, Citadel Advisors LLC lifted its stake in shares of Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 36,206 shares during the period. 10.40% of the stock is currently owned by hedge funds and other institutional investors.
Evogene Company Profile
Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.
In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.
Further Reading
- Five stocks we like better than Evogene
- Elon Musk already made me a “wealthy man”
- Elon’s Secret AI Partner?
- Silver $500? The “Deficit Math” says it’s possible.
- Elon Musk: This Could Turn $100 into $100,000
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
